Prospective trial of sacral neuromodulation for refractory overactive bladder syndrome in Korean patients

Kyung Hyun Moon, Ji Yeon Han, Jang Hwan Kim, Ha Na Lee, Kyu Sung Lee, Jeong Gu Lee, Seung June Oh, Ha Na Yoon, Myung Soo Choo

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objectives: To evaluate the efficacy and safety of sacral neuromodulation for treating patients with refractory overactive bladder based on urodynamic data. Methods: Patients older than 18years of age, with overactive bladder symptoms refractory to conventional therapies were eligible. Patients with more than a 50% reduction in frequency, urgency, or urge incontinence symptoms during a 2-week test stimulation period retained the sacral neuromodulation. Voiding diaries, overactive bladder questionnaires, and urodynamic studies were performed before and 1year after sacral neuromodulation. Results: Forty patients received sacral neuromodulation and 31 patients of those were followed more than 1year. The mean age of the 31 patients was 54.2±15.4 (range, 30-76)years, and the mean duration of symptoms was 4.4±5.7 (range, 1-31)years. After 12months of sacral neuromodulation, significant decreases in the episodes of daily urgency (from 20.2 to 5.7, P<0.001), urgency incontinence (from 7.3 to 0.2; P=0.011), day time micturition (from 21.8 to 9.9; P<0.001), night time micturition (from 3.2 to 1.2; P=0.006) and in severity of urgency episodes (from 3.8 to 2.7; P=0.015) were observed compared to baseline. Significant increases occurred in bladder volume at the first unstable contraction (from 182.4±92.7 to 216.8±115.6mL), bladder volume at first desire to void (from 150.5±90.8 to 167.8±81.5mL), maximal cystometric capacity (from 260.7±120.4 to 291.7±124.3mL) and bladder volume at urgency sensation (from 182.4±92.7 to 208.2±106.6mL) (all P<0.05). Conclusions: Sacral neuromodulation is an effective and safe treatment for refractory overactive bladder.

Original languageEnglish
Pages (from-to)175-179
Number of pages5
JournalLUTS: Lower Urinary Tract Symptoms
Volume6
Issue number3
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Overactive Urinary Bladder
Urinary Bladder
Urination
Urodynamics
Urge Urinary Incontinence
Safety
Therapeutics

Keywords

  • Efficacy
  • Overactive bladder
  • Sacral neuromodulation

ASJC Scopus subject areas

  • Urology
  • Neurology

Cite this

Prospective trial of sacral neuromodulation for refractory overactive bladder syndrome in Korean patients. / Moon, Kyung Hyun; Han, Ji Yeon; Kim, Jang Hwan; Lee, Ha Na; Lee, Kyu Sung; Lee, Jeong Gu; Oh, Seung June; Yoon, Ha Na; Choo, Myung Soo.

In: LUTS: Lower Urinary Tract Symptoms, Vol. 6, No. 3, 01.01.2014, p. 175-179.

Research output: Contribution to journalArticle

Moon, Kyung Hyun ; Han, Ji Yeon ; Kim, Jang Hwan ; Lee, Ha Na ; Lee, Kyu Sung ; Lee, Jeong Gu ; Oh, Seung June ; Yoon, Ha Na ; Choo, Myung Soo. / Prospective trial of sacral neuromodulation for refractory overactive bladder syndrome in Korean patients. In: LUTS: Lower Urinary Tract Symptoms. 2014 ; Vol. 6, No. 3. pp. 175-179.
@article{8b7837dfd3a14921acd5df80d5b65e8c,
title = "Prospective trial of sacral neuromodulation for refractory overactive bladder syndrome in Korean patients",
abstract = "Objectives: To evaluate the efficacy and safety of sacral neuromodulation for treating patients with refractory overactive bladder based on urodynamic data. Methods: Patients older than 18years of age, with overactive bladder symptoms refractory to conventional therapies were eligible. Patients with more than a 50{\%} reduction in frequency, urgency, or urge incontinence symptoms during a 2-week test stimulation period retained the sacral neuromodulation. Voiding diaries, overactive bladder questionnaires, and urodynamic studies were performed before and 1year after sacral neuromodulation. Results: Forty patients received sacral neuromodulation and 31 patients of those were followed more than 1year. The mean age of the 31 patients was 54.2±15.4 (range, 30-76)years, and the mean duration of symptoms was 4.4±5.7 (range, 1-31)years. After 12months of sacral neuromodulation, significant decreases in the episodes of daily urgency (from 20.2 to 5.7, P<0.001), urgency incontinence (from 7.3 to 0.2; P=0.011), day time micturition (from 21.8 to 9.9; P<0.001), night time micturition (from 3.2 to 1.2; P=0.006) and in severity of urgency episodes (from 3.8 to 2.7; P=0.015) were observed compared to baseline. Significant increases occurred in bladder volume at the first unstable contraction (from 182.4±92.7 to 216.8±115.6mL), bladder volume at first desire to void (from 150.5±90.8 to 167.8±81.5mL), maximal cystometric capacity (from 260.7±120.4 to 291.7±124.3mL) and bladder volume at urgency sensation (from 182.4±92.7 to 208.2±106.6mL) (all P<0.05). Conclusions: Sacral neuromodulation is an effective and safe treatment for refractory overactive bladder.",
keywords = "Efficacy, Overactive bladder, Sacral neuromodulation",
author = "Moon, {Kyung Hyun} and Han, {Ji Yeon} and Kim, {Jang Hwan} and Lee, {Ha Na} and Lee, {Kyu Sung} and Lee, {Jeong Gu} and Oh, {Seung June} and Yoon, {Ha Na} and Choo, {Myung Soo}",
year = "2014",
month = "1",
day = "1",
doi = "10.1111/luts.12036",
language = "English",
volume = "6",
pages = "175--179",
journal = "LUTS: Lower Urinary Tract Symptoms",
issn = "1757-5664",
publisher = "Wiley Blackwell",
number = "3",

}

TY - JOUR

T1 - Prospective trial of sacral neuromodulation for refractory overactive bladder syndrome in Korean patients

AU - Moon, Kyung Hyun

AU - Han, Ji Yeon

AU - Kim, Jang Hwan

AU - Lee, Ha Na

AU - Lee, Kyu Sung

AU - Lee, Jeong Gu

AU - Oh, Seung June

AU - Yoon, Ha Na

AU - Choo, Myung Soo

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Objectives: To evaluate the efficacy and safety of sacral neuromodulation for treating patients with refractory overactive bladder based on urodynamic data. Methods: Patients older than 18years of age, with overactive bladder symptoms refractory to conventional therapies were eligible. Patients with more than a 50% reduction in frequency, urgency, or urge incontinence symptoms during a 2-week test stimulation period retained the sacral neuromodulation. Voiding diaries, overactive bladder questionnaires, and urodynamic studies were performed before and 1year after sacral neuromodulation. Results: Forty patients received sacral neuromodulation and 31 patients of those were followed more than 1year. The mean age of the 31 patients was 54.2±15.4 (range, 30-76)years, and the mean duration of symptoms was 4.4±5.7 (range, 1-31)years. After 12months of sacral neuromodulation, significant decreases in the episodes of daily urgency (from 20.2 to 5.7, P<0.001), urgency incontinence (from 7.3 to 0.2; P=0.011), day time micturition (from 21.8 to 9.9; P<0.001), night time micturition (from 3.2 to 1.2; P=0.006) and in severity of urgency episodes (from 3.8 to 2.7; P=0.015) were observed compared to baseline. Significant increases occurred in bladder volume at the first unstable contraction (from 182.4±92.7 to 216.8±115.6mL), bladder volume at first desire to void (from 150.5±90.8 to 167.8±81.5mL), maximal cystometric capacity (from 260.7±120.4 to 291.7±124.3mL) and bladder volume at urgency sensation (from 182.4±92.7 to 208.2±106.6mL) (all P<0.05). Conclusions: Sacral neuromodulation is an effective and safe treatment for refractory overactive bladder.

AB - Objectives: To evaluate the efficacy and safety of sacral neuromodulation for treating patients with refractory overactive bladder based on urodynamic data. Methods: Patients older than 18years of age, with overactive bladder symptoms refractory to conventional therapies were eligible. Patients with more than a 50% reduction in frequency, urgency, or urge incontinence symptoms during a 2-week test stimulation period retained the sacral neuromodulation. Voiding diaries, overactive bladder questionnaires, and urodynamic studies were performed before and 1year after sacral neuromodulation. Results: Forty patients received sacral neuromodulation and 31 patients of those were followed more than 1year. The mean age of the 31 patients was 54.2±15.4 (range, 30-76)years, and the mean duration of symptoms was 4.4±5.7 (range, 1-31)years. After 12months of sacral neuromodulation, significant decreases in the episodes of daily urgency (from 20.2 to 5.7, P<0.001), urgency incontinence (from 7.3 to 0.2; P=0.011), day time micturition (from 21.8 to 9.9; P<0.001), night time micturition (from 3.2 to 1.2; P=0.006) and in severity of urgency episodes (from 3.8 to 2.7; P=0.015) were observed compared to baseline. Significant increases occurred in bladder volume at the first unstable contraction (from 182.4±92.7 to 216.8±115.6mL), bladder volume at first desire to void (from 150.5±90.8 to 167.8±81.5mL), maximal cystometric capacity (from 260.7±120.4 to 291.7±124.3mL) and bladder volume at urgency sensation (from 182.4±92.7 to 208.2±106.6mL) (all P<0.05). Conclusions: Sacral neuromodulation is an effective and safe treatment for refractory overactive bladder.

KW - Efficacy

KW - Overactive bladder

KW - Sacral neuromodulation

UR - http://www.scopus.com/inward/record.url?scp=84926176484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926176484&partnerID=8YFLogxK

U2 - 10.1111/luts.12036

DO - 10.1111/luts.12036

M3 - Article

VL - 6

SP - 175

EP - 179

JO - LUTS: Lower Urinary Tract Symptoms

JF - LUTS: Lower Urinary Tract Symptoms

SN - 1757-5664

IS - 3

ER -